Document is current
Any future updates will be listed below
-
Authors
Jernbom Falk, August https://orcid.org/0000-0002-7773-1851
Galletly, Cherrie https://orcid.org/0000-0001-6185-9677
Just, David https://orcid.org/0000-0001-6126-2256
Toben, Catherine
Baune, Bernhard T.
Clark, Scott R. https://orcid.org/0000-0003-1640-5611
Liu, Dennis
Nilsson, Peter https://orcid.org/0000-0002-4657-8532
Månberg, Anna https://orcid.org/0000-0002-0056-1313
Schubert, K. Oliver https://orcid.org/0000-0003-1690-0209
- License Information
-
More Information
Article History
Received: 6 March 2021
Revised: 12 August 2021
Accepted: 26 August 2021
First Online: 13 September 2021
Competing interests
: AJF, AM, DJ, PN, CT, and CG report no competing interests. BTB reports having received speaker and consultation fees from AstraZeneca, Lundbeck, Pfizer, Takeda, Servier, Bristol Myers Squibb, Otsuka, LivaNova, and Janssen-Cilag. SRC reports having received lecture fees and research funding from Janssen Australia; lecture fees, consulting fees and research funding from Lundbeck Otsuka; lecture fees from Servier Australia. DL reports having received lecture and/or consulting fees from Lundbeck, Janssen, Otsuka, Seqirus, and Servier. OS reports having received lecture fees and research funding from Janssen Australia, research funding from Lundbeck Otsuka, and research funding from Gilead.
